Ameltolide, a 4-aminobenzamide derivative, is an experimental anticonvulsant agent, effective at inhibiting seizures in animal models.[1] It is non-toxic at dosing levels and no undesirable side effects are attributable to its application.[2]

Ameltolide
Clinical data
ATC code
  • None
Identifiers
  • 4-Amino-N-(2,6-dimethylphenyl)benzamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H16N2O
Molar mass240.306 g·mol−1
3D model (JSmol)
  • O=C(Nc1c(cccc1C)C)c2ccc(N)cc2
  • InChI=1S/C15H16N2O/c1-10-4-3-5-11(2)14(10)17-15(18)12-6-8-13(16)9-7-12/h3-9H,16H2,1-2H3,(H,17,18)
  • Key:HZIWGOAXOBPQGY-UHFFFAOYSA-N

References edit

  1. ^ Robertson DW, Beedle EE, Krushinski JH, Lawson RR, Parli CJ, Potts B, Leander JD (April 1991). "Synthesis and pharmacological evaluation of a major metabolite of ameltolide, a potent anticonvulsant". Journal of Medicinal Chemistry. 34 (4): 1253–7. doi:10.1021/jm00108a003. PMID 2016702.
  2. ^ Higdon GL, McKinley ER, Markham JK (July 1991). "Ameltolide. I: Developmental toxicology studies of a novel anticonvulsant". Teratology. 44 (1): 37–44. doi:10.1002/tera.1420440107. PMID 1957261.